-
Mashup Score: 0CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC - 4 year(s) ago
Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses CLEOPATRA (NCT00567190), a phase III, randomized, double-blind, placebo-controlled study…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
Pedro Gouveia, MD, of the Champalimaud Foundation, Lisbon, Portugal, discusses the growing importance of e-health technology in the face of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: The impact of coronavirus on patient-doctor interactions in Portugal w/ Pedro Gouveia of @ChampalimaudF: https://t.co/PvIfq8PDOj @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert
-
-
Mashup Score: 0LILAC: comparing cardiac safety of ABP 980 with trastuzumab - 4 year(s) ago
Hans-Christian Kolberg, MD, PhD, of Marienhospital Bottrop, Bottrop, Germany, discusses LILAC, a randomized, double-blind, active-controlled study (NCT01901146) investigating the cardiac…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: LILAC: comparing cardiac safety of ABP 980 with trastuzumab w/ Hans-Christian Kolberg of Marienhospital Bottrop: https://t.co/v30zrzLDGk @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer #ImmunoOnc
-
-
Mashup Score: 5The future of breast cancer treatment - 4 year(s) ago
Gaia Griguolo, MD, of the Istituto Oncologico Veneto, Padua, Italy, discusses the future of breast cancer treatment. This interview was…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: The future of breast cancer treatment w/ @GaiaGriguolo of @I_love_IOV: https://t.co/lpIROLHQWv @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer
-
-
Mashup Score: 1The Oncoplastic Breast Consortium - 4 year(s) ago
Walter P. Weber, MD, PhD, of Basel University Hospital, Basel, Switzerland, discusses the Oncoplastic Breast Consortium, a group of breast…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: The Oncoplastic Breast Consortium w/ Walter Weber of @UniSpitalBasel: https://t.co/bNC5nAJD93 @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer
-
-
Mashup Score: 0Unmet needs in breast cancer - 4 year(s) ago
Giuseppe Curigliano, MD, PhD, University of Milano, Milan, Italy, talks on where the current unmet needs in breast cancer are,…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Unmet needs in #BreastCancer w/ @curijoey of @IEOufficiale: https://t.co/SbOZZ8cyyp @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert
-
-
Mashup Score: 0LILAC: comparing cardiac safety of ABP 980 with trastuzumab - 4 year(s) ago
Hans-Christian Kolberg, MD, PhD, of Marienhospital Bottrop, Bottrop, Germany, discusses LILAC, a randomized, double-blind, active-controlled study (NCT01901146) investigating the cardiac…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: LILAC: comparing cardiac safety of ABP 980 with trastuzumab w/ Hans-Christian Kolberg w/ of Marienhospital Bottrop: https://t.co/HzWI1DMMUE @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer
-
-
Mashup Score: 2SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC - 4 year(s) ago
Thomas Bachelot, MD, PhD, of Centre Léon Bérard, Lyon, France, discusses a subgroup analyses of the SAFIR02-IMMUNO study (NCT02299999) which…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: SAFIR02-IMMUNO: PDL1 copy number changes predicts checkpoint blockade inhibitor efficacy in mBC w/ Thomas Bachelot w/ @CLCCLeonBerard: https://t.co/aW9Zi6B0Bj @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #BreastCancer #ImmunoOnc
-
-
Mashup Score: 2CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC - 4 year(s) ago
Sandra Swain, MD, FACP, Georgetown University Medical Center, Washington, DC, discusses CLEOPATRA (NCT00567190), a phase III, randomized, double-blind, placebo-controlled study…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ metastatic #BreastCancer w/ Sandra Swain of @gumedcenter: https://t.co/ArGu37etqO @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert #ImmunoOnc
-
-
Mashup Score: 0Pembro plus palliative radio for HR+ mBC - 4 year(s) ago
Sara Tolaney, MD, MPH, Dana Farber Cancer Institute, Boston, MA, discusses pembrolizumab (pembro) in combination with palliative radiotherapy (radio) for…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
VIDEO: Pembro plus palliative radio for HR+ metastatic #BreastCancer w/ @stolaney1 of @DanaFarber: https://t.co/ICSwKaO56q @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert
-
VIDEO: CLEOPATRA: pertuzumab, trastuzumab & chemo for HER2+ mBC w/ Sandra Swain of @gumedcenter: https://t.co/MLyRfDBBL5 @VJOncology @myESMO #BCsm #VirtualMeeting #ESMOBreast20 #OncoAlert @OncoAlert